A comprehensive clinical review of opioid-induced allodynia: Discussion of the current evidence and clinical implications

Corey J. Hayes, PharmD, MPH; Jacob T. Painter, PharmD, MBA, PhD

doi:10.5055/jom.2017.0373

Authors

Corey J. Hayes, PharmD, MPH
Jacob T. Painter, PharmD, MBA, PhD

DOI:

https://doi.org/10.5055/jom.2017.0373

Keywords:

allodynia, opioid induced, clinical review

Abstract

Opioid analgesics are one of the most often prescribed medication classes, and their use has increased dramatically, with the number of prescriptions doubling between 1998 and 2010. Moreover, long-term use of opioids is becoming more prevalent. The complications arising from opioid use have been clearly documented; however, a relatively unknown complication potentially linked to opioid use is allodynia. This article outlines how research on opioid-induced hyperalgesia has led to the discovery of allodynia. Next, this article provides a detailed review of the current literature on allodynia, which includes animal studies, case reports, case series, and randomized controlled trials. Finally, the authors provide some potential clinical implications and applications for clinicians in regards to prescribing practices of opioids in the presence of allodynia.

Author Biographies

Corey J. Hayes, PharmD, MPH

Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Health Services Research, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas

Jacob T. Painter, PharmD, MBA, PhD

Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas; Research Health Scientist, Center for Mental Healthcare and Outcomes Research, Department of Veterans Affairs, North Little Rock, Arkansas

References

Blondell RD, Azadfard M, Wisniewski AM: Pharmacologic therapy for acute pain. Am Fam Physician. 2013; 87(11): 766-772.

Klepstad P, Kaasa S, Borchgrevink PC: Starting step III opioids for moderate to severe pain in cancer patients: Dose titration: A systematic review. Palliat Med. 2011; 25(5): 424-430.

Fukshansky M, Are M, Burton AW: The role of opioids in cancer pain management. Pain Pract. 2005; 5(1): 43-53.

Braden JB, Fan M-Y, Edlund MJ, et al.: Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: Results from the TROUP study. J Pain. 2008; 9(11): 1026-1035.

Sullivan MD, Edlund MJ, Fan M-Y, et al.: Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008; 138(2): 440-449.

Edlund MJ, Austen MA, Sullivan MD, et al.: Patterns of opioid use for chronic noncancer pain in the Veterans Health Administration from 2009 to 2011. Pain. 2014; 155(11): 2337-2343.

Noble M, Tregear SJ, Treadwell JR, et al.: Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008; 35(2): 214-228.

Furlan AD, Sandoval JA, Mailis-Gagnon A, et al.: Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ. 2006; 174(11): 1589-1594.

Clark JD: Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage. 2002; 23(2): 131-137.

Sites BD, Beach ML, Davis MA: Increases in the use of prescription opioid analgesics and the lack of improvement in disability metrics among users. Reg Anesth Pain Med. 39(1): 6-12.

Longo DL, Volkow ND, McLellan AT: Opioid abuse in chronic pain—Misconceptions and mitigation strategies. N Engl J Med. 2016; 374(13): 1253-1263.

Mcdonald JP, Torrey AJ, Mehta MP, et al.: Beyond respiratory depression and constipation: Adverse effects of opioids. J Miss State Med Assoc. 2015; 56(7): 193-195.

Webster LR: Opioid-Induced Constipation. Pain Med. 2015; 16(suppl 1): S16-S21.

Sullivan MD, Edlund MJ, Fan M-Y, et al.: Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study. Pain. 2010; 150(2): 332-339.

Chou R, Fanciullo GJ, Fine PG, et al.: Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009; 10(2): 131-146.

Sullivan MD, Von Korff M, Banta-Green C, et al.: Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain. 2010; 149(2): 345-353.

Ives TJ, Chelminski PR, Hammett-Stabler CA, et al.: Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006; 6(1): 46.

Lee M, Silverman SM, Hansen H, et al.: A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011; 14(2): 145-161.

Reznikov I, Pud D, Eisenberg E: Oral opioid administration and hyperalgesia in patients with cancer or chronic nonmalignant pain. Br J Clin Pharmacol. 2005; 60(3): 311-318.

Wang H, Akbar M, Weinsheimer N, et al.: Longitudinal observation of changes in pain sensitivity during opioid tapering in patients with chronic low-back pain. Pain Med. 2011; 12(12): 1720-1726.

Wallwork RS, Chipidza FE, Stern TA: Obstacles to the prescription and use of opioids. Prim Care Companion CNS Disord. 2016;18(1).

Rossbach M: Ueber die Gewoehnung an Gifte. Pflugers Arch Gesamte Physiol des Menschen. 1880; 21: 213-225.

Himmelsbach CK: The morphine abstinence syndrome, its nature and treatment. Ann Intern Med. 1941;15(5):829.

Andrews HL: The effect of opiates on the pain threshold in post-addicts. J Clin Invest. 1943; 22(4): 511-516.

Mulé SJ, Clements TH, Layson RC, et al.: Analgesia in guinea pigs: A measure of tolerance development. Arch Int Pharmacodyn Thérapie. 1968; 173(1): 201-212.

Kayan S, Mitchell CL: The effects of chronic morphine administration on tooth pulp thresholds in dogs and cats. Proc Soc Exp Biol Med. 1968; 128(3): 755-760.

Kayan S, Woods LA, Mitchell CL: Morphine-induced hyperalgesia in rats tested on a hot plate. J Pharmacol Exp Ther. 1971; 177(3): 509-513.

Vanderah TW, Gardell LR, Burgess SE, et al.: Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000; 20(18): 7074-7079.

Liang D-Y, Liao G, Wang J, et al.: A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology. 2006; 104(5): 1054-1062.

Silverman SM: Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2011; 12(3): 679-684.

Vanderah TW, Suenaga NM, Ossipov MH, et al.: Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001; 21(1): 279-286.

Mao J, Sung B, Ji R-R, et al.: Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002; 22(18): 8312-8323.

Woolf CJ: Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res. 1981; 209(2): 491-495.

Yaksh TL, Harty GJ, Onofrio BM: High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: Clinical and theoretic implications. Anesthesiology. 1986; 64(5): 590-597.

Arnér S, Rawal N, Gustafsson LL: Clinical experience of long-term treatment with epidural and intrathecal opioids—A nationwide survey. Acta Anaesthesiol Scand. 1988; 32(3): 253-259.

De Conno F, Caraceni A, Martini C, et al.: Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain. 1991; 47(3): 337-339.

Sjøgren P, Jonsson T, Jensen NH, et al.: Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain. 1993; 55(1): 93-97.

Sjøgren P, Jensen NH, Jensen TS: Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994; 59(2): 313-316.

Lawlor P, Walker P, Bruera E, et al.: Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage. 1997; 13(6): 356-361.

Sjøgren P, Thunedborg LP, Christrup L, et al.: Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administrationϿ. Six case histories. Acta Anaesthesiol Scand. 1998; 42(9): 1070-1075.

Heger S, Maier C, Otter K, et al.: Morphine induced allodynia in a child with brain tumour. BMJ. 1999; 319(7210): 627-629.

Parisod E, Siddall PJ, Viney M, et al.: Allodynia after acute intrathecal morphine administration in a patient with neuropathic pain after spinal cord injury. Anesth Analg. 2003; 97(1): 183-186.

Mercadante S, Ferrera P, Villari P, et al.: Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003; 26(2): 769-775.

Bruera E, Pereira J: Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain. 1997; 69(1-2): 199-201.

Devulder J: Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol. 1997; 9(2): 146-148.

Leung A, Wallace MS, Ridgeway B, et al.: Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001; 91(1-2): 177-187.

Sindrup SH, Andersen G, Madsen C, et al.: Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial. Pain. 1999; 83(1): 85-90.

Joly V, Richebe P, Guignard B, et al.: Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005; 103(1): 147-155.

Yildirim V, Doganci S, Cinar S, et al.: Acute high dose-fentanyl exposure produces hyperalgesia and tactile allodynia after coronary artery bypass surgery. Eur Rev Med Pharmacol Sci. 2014; 18(22): 3425-3434.

Marples IL, Murray P: Morphine induced allodynia in child with brain tumour. Signs are more likely to have been due to underlying medical condition. BMJ. 2000; 320(7231): 381.

Hayhurst CJ, Durieux ME: Differential opioid tolerance and opioid-

induced hyperalgesia. Anesthesiology. 2016; 124(2): 483-488.

Guignard B, Bossard AE, Coste C, et al.: Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000; 93(2): 409-417.

Crawford MW, Hickey C, Zaarour C, et al.: Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth Analg. 2006; 102(6): 1662-1667.

McDonnell C, Zaarour C, Hull R, et al.: Pre-treatment with morphine does not prevent the development of remifentanil-induced hyperalgesia. Can J Anesth Can d’anesthésie. 2008; 55(12): 813-818.

Schlimp CJ, Pipam W, Wolrab C, et al.: Clonidin bei Remifentanil-induzierter Hyperalgesie. Der Schmerz. 2011; 25(3): 290-295.

Yu Z, Wu W, Wu X, et al.: Protective effects of dexmedetomidine combined with flurbiprofen axetil on remifentanil-induced hyperalgesia: A randomized controlled trial. Exp Ther Med. 2016; 12(4): 2622-2628.

Zhang L, Shu R, Zhao Q, et al.: Preoperative but not postoperative flurbiprofen axetil alleviates remifentanil induced hyperalgesia after laparoscopic gynecological surgery. Clin J Pain. 2017 (in press).

Chen Y, Yao Y, Wu Y, et al.: Transcutaneous electric acupoint stimulation alleviates remifentanil-induced hyperalgesia in patients undergoing thyroidectomy: A randomized controlled trial. Int J Clin Exp Med. 2015; 8(4): 5781-5787.

Leal PC, Salomão R, Brunialti MKC, et al.: Evaluation of the effect of ketamine on remifentanil-induced hyperalgesia: a double-blind, randomized study. J Clin Anesth. 2015; 27(4): 331-337.